Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a rare lung disease characterised by progressive loss of lung function, dyspnoea and cough. IPF has a variable clinical course but a poor prognosis. Nintedanib, a tyrosine kinase inhibitor, is one of two drugs approved for the treatment of IPF. In clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajari Case, Amy, Johnson, Peace
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Interstitial Lung Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531305/
https://www.ncbi.nlm.nih.gov/pubmed/28883926
http://dx.doi.org/10.1136/bmjresp-2017-000192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531305/
https://www.ncbi.nlm.nih.gov/pubmed/28883926
http://dx.doi.org/10.1136/bmjresp-2017-000192

Ejemplares similares